Thyroid hormone levels during long-term GH treatment in 240 children with PWS.
| . | After 2 years . | After 3 years . | After 4 years . | After 5 years . | After 6 years . | After 7 years . | After 8 years . | After 9 years . | After 10 years . | P-valuea . |
|---|---|---|---|---|---|---|---|---|---|---|
| FT4 pmol/L | 15.87 (15.49-16.24) | 15.95 (15.51-16.38) | 15.77 (15.36-16.18) | 15.63 (15.19-16.06) | 16.10 (15.65-16.56) | 15.62 (15.18-16.05) | 15.48 (15.06-15.91) | 15.79 (15.27-16.32) | 15.83 (15.31-16.35) | .13 |
| FT4 SDS | −0.87 (−0.98 to −0.77) | −0.85 (−0.97 to −0.73) | −0.90 (−1.01 to −0.78) | −0.94 (−1.06 to −0.82) | −0.80 (−1.06 to −0.82) | −0.94 (−1.06 to −0.82) | −0.98 (−1.09 to −0.86) | −0.89 (−1.04 to −0.75) | −0.88 (−1.03 to −0.74) | .13 |
| T3 nmol/L | 2.67 (2.59-2.76) | 2.56 (2.47-2.64) | 2.51 (2.44-2.59) | 2.55 (2.45-2.66) | 2.46 (2.37-2.54) | .00 | ||||
| T3 SDS | 0.37 (0.22-0.52) | 0.20 (0.04-0.35) | 0.16 (0.03-0.29) | 0.27 (0.09-0.46) | 0.12 (−0.03-0.27) | .02 | ||||
| TSH mU/L | 1.99 (1.83-2.15) | 1.94 (1.81-2.08) | 1.92 (1.79-2.05) | 1.89 (1.75-2.04) | 1.89 (1.75-2.04) | 1.78 (1.63-1.92) | 1.63 (1.50-1.76) | 1.67 (1.46-1.88) | 1.61 (1.46-1.75) | .00 |
| TSH SDS | −0.35 (−0.50 to −0.21) | −0.35 (−0.48 to −0.21) | −0.33 (−0.45 to −0.21) | −0.40 (−0.54 to −0.36) | −0.39 (−0.53 to −0.25) | −0.51 (−0.65 to −0.36) | −0.64 (−0.78 to −0.50) | −0.67 (−0.84 to −0.50) | −0.68 (−0.84 to −0.53) | .00 |
| . | After 2 years . | After 3 years . | After 4 years . | After 5 years . | After 6 years . | After 7 years . | After 8 years . | After 9 years . | After 10 years . | P-valuea . |
|---|---|---|---|---|---|---|---|---|---|---|
| FT4 pmol/L | 15.87 (15.49-16.24) | 15.95 (15.51-16.38) | 15.77 (15.36-16.18) | 15.63 (15.19-16.06) | 16.10 (15.65-16.56) | 15.62 (15.18-16.05) | 15.48 (15.06-15.91) | 15.79 (15.27-16.32) | 15.83 (15.31-16.35) | .13 |
| FT4 SDS | −0.87 (−0.98 to −0.77) | −0.85 (−0.97 to −0.73) | −0.90 (−1.01 to −0.78) | −0.94 (−1.06 to −0.82) | −0.80 (−1.06 to −0.82) | −0.94 (−1.06 to −0.82) | −0.98 (−1.09 to −0.86) | −0.89 (−1.04 to −0.75) | −0.88 (−1.03 to −0.74) | .13 |
| T3 nmol/L | 2.67 (2.59-2.76) | 2.56 (2.47-2.64) | 2.51 (2.44-2.59) | 2.55 (2.45-2.66) | 2.46 (2.37-2.54) | .00 | ||||
| T3 SDS | 0.37 (0.22-0.52) | 0.20 (0.04-0.35) | 0.16 (0.03-0.29) | 0.27 (0.09-0.46) | 0.12 (−0.03-0.27) | .02 | ||||
| TSH mU/L | 1.99 (1.83-2.15) | 1.94 (1.81-2.08) | 1.92 (1.79-2.05) | 1.89 (1.75-2.04) | 1.89 (1.75-2.04) | 1.78 (1.63-1.92) | 1.63 (1.50-1.76) | 1.67 (1.46-1.88) | 1.61 (1.46-1.75) | .00 |
| TSH SDS | −0.35 (−0.50 to −0.21) | −0.35 (−0.48 to −0.21) | −0.33 (−0.45 to −0.21) | −0.40 (−0.54 to −0.36) | −0.39 (−0.53 to −0.25) | −0.51 (−0.65 to −0.36) | −0.64 (−0.78 to −0.50) | −0.67 (−0.84 to −0.50) | −0.68 (−0.84 to −0.53) | .00 |
Data are expressed as estimated marginal means (95% CI).
Abbreviations: PWS, Prader–Willi syndrome; SDS, standard deviation score.
aP-value of the change from year 2 to 10 and from year 2 to 6 of GH treatment.
Thyroid hormone levels during long-term GH treatment in 240 children with PWS.
| . | After 2 years . | After 3 years . | After 4 years . | After 5 years . | After 6 years . | After 7 years . | After 8 years . | After 9 years . | After 10 years . | P-valuea . |
|---|---|---|---|---|---|---|---|---|---|---|
| FT4 pmol/L | 15.87 (15.49-16.24) | 15.95 (15.51-16.38) | 15.77 (15.36-16.18) | 15.63 (15.19-16.06) | 16.10 (15.65-16.56) | 15.62 (15.18-16.05) | 15.48 (15.06-15.91) | 15.79 (15.27-16.32) | 15.83 (15.31-16.35) | .13 |
| FT4 SDS | −0.87 (−0.98 to −0.77) | −0.85 (−0.97 to −0.73) | −0.90 (−1.01 to −0.78) | −0.94 (−1.06 to −0.82) | −0.80 (−1.06 to −0.82) | −0.94 (−1.06 to −0.82) | −0.98 (−1.09 to −0.86) | −0.89 (−1.04 to −0.75) | −0.88 (−1.03 to −0.74) | .13 |
| T3 nmol/L | 2.67 (2.59-2.76) | 2.56 (2.47-2.64) | 2.51 (2.44-2.59) | 2.55 (2.45-2.66) | 2.46 (2.37-2.54) | .00 | ||||
| T3 SDS | 0.37 (0.22-0.52) | 0.20 (0.04-0.35) | 0.16 (0.03-0.29) | 0.27 (0.09-0.46) | 0.12 (−0.03-0.27) | .02 | ||||
| TSH mU/L | 1.99 (1.83-2.15) | 1.94 (1.81-2.08) | 1.92 (1.79-2.05) | 1.89 (1.75-2.04) | 1.89 (1.75-2.04) | 1.78 (1.63-1.92) | 1.63 (1.50-1.76) | 1.67 (1.46-1.88) | 1.61 (1.46-1.75) | .00 |
| TSH SDS | −0.35 (−0.50 to −0.21) | −0.35 (−0.48 to −0.21) | −0.33 (−0.45 to −0.21) | −0.40 (−0.54 to −0.36) | −0.39 (−0.53 to −0.25) | −0.51 (−0.65 to −0.36) | −0.64 (−0.78 to −0.50) | −0.67 (−0.84 to −0.50) | −0.68 (−0.84 to −0.53) | .00 |
| . | After 2 years . | After 3 years . | After 4 years . | After 5 years . | After 6 years . | After 7 years . | After 8 years . | After 9 years . | After 10 years . | P-valuea . |
|---|---|---|---|---|---|---|---|---|---|---|
| FT4 pmol/L | 15.87 (15.49-16.24) | 15.95 (15.51-16.38) | 15.77 (15.36-16.18) | 15.63 (15.19-16.06) | 16.10 (15.65-16.56) | 15.62 (15.18-16.05) | 15.48 (15.06-15.91) | 15.79 (15.27-16.32) | 15.83 (15.31-16.35) | .13 |
| FT4 SDS | −0.87 (−0.98 to −0.77) | −0.85 (−0.97 to −0.73) | −0.90 (−1.01 to −0.78) | −0.94 (−1.06 to −0.82) | −0.80 (−1.06 to −0.82) | −0.94 (−1.06 to −0.82) | −0.98 (−1.09 to −0.86) | −0.89 (−1.04 to −0.75) | −0.88 (−1.03 to −0.74) | .13 |
| T3 nmol/L | 2.67 (2.59-2.76) | 2.56 (2.47-2.64) | 2.51 (2.44-2.59) | 2.55 (2.45-2.66) | 2.46 (2.37-2.54) | .00 | ||||
| T3 SDS | 0.37 (0.22-0.52) | 0.20 (0.04-0.35) | 0.16 (0.03-0.29) | 0.27 (0.09-0.46) | 0.12 (−0.03-0.27) | .02 | ||||
| TSH mU/L | 1.99 (1.83-2.15) | 1.94 (1.81-2.08) | 1.92 (1.79-2.05) | 1.89 (1.75-2.04) | 1.89 (1.75-2.04) | 1.78 (1.63-1.92) | 1.63 (1.50-1.76) | 1.67 (1.46-1.88) | 1.61 (1.46-1.75) | .00 |
| TSH SDS | −0.35 (−0.50 to −0.21) | −0.35 (−0.48 to −0.21) | −0.33 (−0.45 to −0.21) | −0.40 (−0.54 to −0.36) | −0.39 (−0.53 to −0.25) | −0.51 (−0.65 to −0.36) | −0.64 (−0.78 to −0.50) | −0.67 (−0.84 to −0.50) | −0.68 (−0.84 to −0.53) | .00 |
Data are expressed as estimated marginal means (95% CI).
Abbreviations: PWS, Prader–Willi syndrome; SDS, standard deviation score.
aP-value of the change from year 2 to 10 and from year 2 to 6 of GH treatment.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
